Payment overview · 2025
General Payments
$600.12
11 reported records · 5 companies
Healthcare provider profile · identity verified
Barry Brook, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CINCINNATI, OH · NPI 1215993779
Verified facts
What the public records show
CMS Open Payments records show Barry Brook, MD received $600.12 in general payments during 2025 across 11 reported records.
Exact Sciences Corporation accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $144.20 | 24.0% | 7 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $120.31 | 20.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $116.40 | 19.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $109.84 | 18.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $109.37 | 18.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $600.12 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $144.20 | 7 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $120.31 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $116.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $109.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
228 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 859 | 250 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 372 | 117 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 243 | 67 |
| Lisinopril | Lisinopril | 230 | 66 |
| Eliquis | Apixaban | 228 | 39 |
| Losartan Potassium | Losartan Potassium | 223 | 66 |
| Simvastatin | Simvastatin | 222 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 63 |
| Omeprazole | Omeprazole | 207 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 50 |
| Metformin Hcl | Metformin Hcl | 178 | 53 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 172 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 168 | 46 |
| Trazodone Hcl | Trazodone Hcl | 160 | 42 |
| Gabapentin | Gabapentin | 155 | 43 |
| Lorazepam | Lorazepam | 138 | 45 |
| Furosemide | Furosemide | 137 | 51 |
| Metformin Hcl Er | Metformin Hcl | 126 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 47 |
| Clonazepam | Clonazepam | 107 | 21 |
| Sertraline Hcl | Sertraline Hcl | 104 | 25 |
| Farxiga | Dapagliflozin Propanediol | 102 | 22 |
| Mirtazapine | Mirtazapine | 96 | 21 |
| Alendronate Sodium | Alendronate Sodium | 94 | 27 |
| Allopurinol | Allopurinol | 93 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 32 |
| Glimepiride | Glimepiride | 88 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 27 |
| Azithromycin | Azithromycin | 85 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 26 |
| Meloxicam | Meloxicam | 81 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 15 |
| Spironolactone | Spironolactone | 72 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 51 |
| Celecoxib | Celecoxib | 68 | 18 |
| Famotidine | Famotidine | 66 | 17 |
| Potassium Chloride | Potassium Chloride | 66 | 20 |
| Synthroid | Levothyroxine Sodium | 66 | 18 |
| Methylprednisolone | Methylprednisolone | 64 | 54 |
| Torsemide | Torsemide | 64 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 54 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 15 |
| Ozempic | Semaglutide | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 44 | 11 |
| Carvedilol | Carvedilol | 44 | 14 |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Atenolol | Atenolol | 43 | 15 |
| Prednisone | Prednisone | 43 | 27 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 30 |
| Alprazolam | Alprazolam | 41 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 37 |
| Klor-Con M20 | Potassium Chloride | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 11 |
| Montelukast Sodium | Montelukast Sodium | 38 | 16 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Nystatin | Nystatin | 35 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 11 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 11 |
| Amoxicillin | Amoxicillin | 28 | 25 |
| Hydrocortisone | Hydrocortisone | 28 | 12 |
| Linzess | Linaclotide | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | 12 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 18 |
| Cephalexin | Cephalexin | 22 | 15 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | 13 |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $600.12 · 11 records | Exact Sciences Corporation | AIRSUPRA, Cologuard Collection Kit, NURTEC ODT, QULIPTA, TREMFYA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error